Shire (SHPG) Long-Term Debt : $10,741 Mil (As of Sep. 2018)

View and export this data going back to 1998. Start your Free Trial

What is Shire Long-Term Debt?

Shire's Long-Term Debt for the quarter that ended in Sep. 2018 was $10,741 Mil.

Shire's quarterly Long-Term Debt increased from Mar. 2018 ($0 Mil) to Jun. 2018 ($16,383 Mil) but then declined from Jun. 2018 ($16,383 Mil) to Sep. 2018 ($10,741 Mil).

Shire's annual Long-Term Debt increased from Dec. 2015 ($70 Mil) to Dec. 2016 ($19,553 Mil) but then declined from Dec. 2016 ($19,553 Mil) to Dec. 2017 ($16,411 Mil).

Shire Long-Term Debt Historical Data

The historical data trend for Shire's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Long-Term Debt Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Long-Term Debt

Get a 7-Day Free Trial

69.90

19,552.60

16,410.70

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Long-Term Debt	Get a 7-Day Free Trial															17,613.90	16,410.70	-	16,383.20	10,740.70

Shire (NAS:SHPG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Shire Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Shire's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Shire (SHPG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Executives

James H Cavanaugh

director

265 HOTHORPE LANE, VILLANOVA PA 19085